UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q
☒
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the quarterly period ended September 30, 2020
☐
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934
For
the transition period from _______ to _______
Commission
file number: 001-32501
REED’S,
INC .
(Exact
name of registrant as specified in its charter)
Delaware
35-2177773
(State
of
incorporation)
(I.R.S.
Employer
Identification
No.)
201
Merritt 7 , Norwalk , CT . 06851
(Address
of principal executive offices) (Zip Code)
(800)
997-3337
(Registrant’s
telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class
Trading
Symbol
Names
of each exchange on which registered
Common
Stock
REED
NASDAQ
Indicate
the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: There
were a total of 62,967,570 shares of Common Stock outstanding as of October 31, 2020.
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Yes
☒ No ☐
Indicate
by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files). Yes ☒ No ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large
Accelerated Filer ☐
Accelerated
Filer ☒
Non-Accelerated
Filer (do not check if Smaller Reporting Company) ☐
Smaller
Reporting Company ☒
Emerging
Growth Company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the issuer is a shell company (as defined in Rule 12b-2 of the Exchange
Act). Yes ☐ No ☒
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS
This Quarterly Report on Form 10-Q, including
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 2 of Part I
of this report as well as our other public filings or public statements include forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by terms and phrases such as
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “should,”
and “will” and similar expressions and include references to assumptions and relate to our future prospects, developments
and business strategies.
These forward-looking statements involve
known and unknown risks, assumptions and uncertainties and other factors that may cause our actual results, levels of activity,
performance or achievements to be materially different from any future results, levels of activity, performance, or achievements
expressed or implied by forward-looking statements. These risks, assumptions and uncertainties include difficulty in marketing
Reed’s products and services, maintaining and protecting brand recognition, Reed’s ability to qualify for forgiveness
of the PPP loan, the need for significant capital, dependence on third party distributors, dependence on third party brewers,
increasing costs of fuel and freight, protection of intellectual property, competition and other factors, any of which could have
an adverse effect on the business plans of Reed’s, its reputation in the industry or its expected financial return from
operations and results of operations. These risks, assumptions and uncertainties are not necessarily all of the important factors
that could cause actual results to differ materially from those expressed in any of our forward-looking statements.
We undertake no obligation to update or
revise the forward-looking statements included in this report, whether as a result of new information, future events or otherwise,
after the date of this report. Our actual results, performance or achievements could differ materially from the results expressed
in, or implied by, these forward-looking statements. Factors that could cause or contribute to such differences are discussed
in the section entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition
and Results of Operations” included herein and included in our Annual Report on Form 10-K for the fiscal year ended December
31, 2019, which we filed with the SEC on March 18, 2020, as amended April 8, 2020, and our Quarterly Reports on Form 10-Q for
periods ended March 30, 2020 and June 30, 2020, which we filed on May 12, 2020 and August 10, 2020. These documents are available
on the SEC’s website at www.sec.gov.
i
TABLE
OF CONTENTS
PART
I - FINANCIAL INFORMATION
F-1
Item
1. Condensed Financial Statements
F-1
Condensed
Balance Sheets – September 30, 2020 (unaudited) and December 31, 2019
F-1
Condensed
Statements of Operations for the three and nine months ended September 30, 2020 and 2019 (unaudited)
F-2
Condensed
Statements of Changes in Stockholders’ Equity (Deficit) for the three and nine months ended September 30, 2020 and 2019
(unaudited)
F-3
Condensed
Statements of Cash Flows for the nine months ended September 30, 2020 and 2019 (unaudited)
F-4
Notes
to Condensed Financial Statements (unaudited)
F-5
Item
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
1
Item
3. Quantitative and Qualitative Disclosures About Market Risk
11
Item
4. Controls and Procedures
11
PART
II - OTHER INFORMATION
12
Item
1. Legal Proceedings
12
Item
1A. Risk Factors
12
Item
2. Unregistered Sales of Equity Securities and Use of Proceeds
14
Item
3. Defaults Upon Senior Securities
14
Item
4. Mine Safety Disclosures
14
Item
5. Other Information
14
Item
6. Exhibits
14
ii
Part
I – FINANCIAL INFORMATION
Item
1. Financial Statements
REED’S
INC.
CONDENSED
BALANCE SHEETS
(Amounts
in thousands, except share amounts)
September
30,
2020
December
31,
2019
(Unaudited)
ASSETS
Current
assets:
Cash
$
875
$ 913
Accounts
receivable, net of allowance for doubtful accounts and returns and discounts of $ 194 and $ 375 , respectively
4,647
2,099
Receivable
from related party
391
356
Inventory,
net of reserve for obsolescence of $ 224
and $ 646 ,
respectively
9,436
10,508
Prepaid
expenses and other current assets
704
420
Total
current assets
16,053
14,296
Property
and equipment, net of accumulated depreciation of $ 316 and $ 482 , respectively
984
1,053
Equipment
held for sale, net of impairment reserves of $ 96 and $ 96 , respectively
67
67
Intangible
assets
613
576
Total
assets
$
17,717
$ 15,992
LIABILITIES
AND STOCKHOLDERS’ EQUITY
Current
liabilities:
Accounts
payable
$
5,441
$ 5,539
Accrued
expenses
835
646
Revolving
line of credit
4,272
3,177
Current
portion of note payable
470
-
Convertible
note to a related party
5,128
-
Current
portion of leases payable
114
49
Total
current liabilities
16,260
9,411
Leases
payable, less current portion
592
737
Convertible
note to a related party
-
4,689
Note
payable
300
-
Warrant
liability
7
8
Total
liabilities
17,159
14,845
Stockholders’
equity:
Series
A Convertible Preferred stock, $ 10 par value, 500,000 shares authorized, 9,411 shares issued and outstanding
94
94
Common
stock, $ .0001 par value, 100,000,000 and 100,000,000 shares authorized, respectively; 62,960,570 and 47,595,206 shares issued
and outstanding, respectively
6
5
Common stock
issuable, 350,000 shares at September 30, 2020
285
-
Additional
paid in capital
83,646
77,596
Accumulated
deficit
( 83,473 )
( 76,548 )
Total
stockholders’ equity
558
1,147
Total
liabilities and stockholders’ equity
$
17,717
$ 15,992
The
accompanying notes are an integral part of these condensed financial statements.
F- 1
REED’S,
INC.
CONDENSED
STATEMENTS OF OPERATIONS
For
the Three and Nine Months Ended September 30, 2020 and 2019
(Unaudited)
(Amounts
in thousands, except share and per share amounts)
2020
2019
2020
2019
Three
Months Ended
September
30,
Nine
Months Ended
September
30,
2020
2019
2020
2019
Net
Sales
$
10,562
$ 8,740
$
30,938
$ 26,669
Cost
of goods sold
7,176
6,238
21,694
19,390
Gross
profit
3,386
2,502
9,244
7,279
Operating
expenses:
Delivery
and handling expense
2,207
1,902
4,950
4,369
Selling
and marketing expense
1,872
2,508
5,382
7,718
General
and administrative expense
1,583
2,470
4,872
6,557
Total
operating expenses
5,662
6,880
15,204
18,644
Loss
from operations
( 2,276 )
( 4,378 )
( 5,960 )
( 11,365 )
Interest
expense
( 322 )
( 318 )
( 961 )
( 947 )
Change
in fair value of warrant liability
8
131
1
23
Net
loss
( 2,590 )
( 4,565 )
( 6,920 )
( 12,289 )
Dividends
on Series A Convertible Preferred Stock
-
-
( 5 )
( 5 )
Net
Loss Attributable to Common Stockholders
$
( 2,590 )
$ ( 4,565 )
$
( 6,925 )
$ ( 12,294 )
Loss
per share – basic and diluted
$
( 0.04 )
$ ( 0.14 )
$
( 0.12 )
$ ( 0.38 )
Weighted average
number of shares outstanding – basic and diluted
62,940,091
33,716,359
56,706,141
32,179,119
The
accompanying notes are an integral part of these condensed financial statements.
F- 2
REED’S,
INC.
CONDENSED
STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)
For
the Three and Nine months Ended September 30, 2020 and 2019
(Unaudited)
(Amounts
in thousands except share amounts)
Common
Stock Shares
Common
Stock Amount
Preferred
Stock Shares
Preferred
Stock Amount
Common
Stock Issuable Shares
Common
Stock Issuable Amount
Additional
Paid In Capital
Accumulated
Deficit
Total
Stockholders’ Equity (Deficit)
Common
Stock
Preferred
Stock
Common
Stock Issuable
Additional
Paid In
Accumulated
Total
Stockholders’
Equity
Shares
Amount
Shares
Amount
Shares
Amount
Capital
Deficit
(Deficit)
Balance,
June 30, 2020
62,928,540
$ 6
9,411
$ 94
350,000
$ 285
$ 83,364
$ ( 80,883 )
$ 2,866
Fair
value of vested options
-
-
-
263
263
Common
shares issued on exercise of options
27,500
-
14
14
Issuance
of shares for dividends on Series A Convertible Preferred Stock
4,530
-
-
5
-
5
Fair value of vested restricted shares
granted to officers for services
Fair value of vested restricted shares granted to
officers for services, shares
Common shares issued pursuant to the rights offering, net of offering costs
Common shares issued pursuant to the
rights offering, net of offering costs, shares
Shares granted to Directors for services
Shares granted to Directors for
services, shares
Exercise of warrants
-
-
-
Net
Loss
( 2,590 )
( 2,590 )
Balance,
September 30, 2020
62,960,570
$ 6
9,411
$ 94
350,000
$ 285
$ 83,646
$ ( 83,473 )
$ 558
Common
Stock
Preferred
Stock
Common
Stock
Issuable
Additional
Paid In
Accumulated
Total
Stockholders’
Equity
Shares
Amount
Shares
Amount
Shares
Amount
Capital
Deficit
(Deficit)
Balance,
December 31, 2019
47,595,206
$ 5
9,411
$ 94
-
$ -
$ 77,596
$ ( 76,548 )
$ 1,147
Fair
value of vested options
-
-
722
722
Fair
value of vested restricted shares granted to officers
-
-
350,000
285
285
Dividends
on Series A Convertible Preferred Stock
4,530
-
-
5
( 5 )
-
Common
shares issued on exercise of options
27,500
-
14
14
Common
shares issued pursuant to the rights offering, net of offering costs
15,333,334
1
-
-
5,309
-
5,310
Exercise of warrants
-
Net
Loss
( 6,920 )
( 6,920 )
Balance,
September 30, 2020
62,960,570
$ 6
9,411
$ 94
350,000
$ 285
$ 83,646
$ ( 83,473 )
$ 558
Common
Stock
Preferred
Stock
Common
Stock
Issuable
Additional
Paid In
Accumulated
Total
Stockholders’
Equity
Shares
Amount
Shares
Amount
Shares
Amount
Capital
Deficit
(Deficit)
Balance,
June 30, 2019
33,708,826
$ 3
9,411
$ 94
-
$ -
$ 70,051
$ ( 68,160 )
$ 1,988
Fair
value of vested options
-
223
223
Shares
granted to Directors for services
8,072
-
-
-
-
29
29
Fair
value of vested restricted shares granted to an officer for services
-
-
-
-
116
116
Exercise
of warrants
3,146
-
1
1
Net
Loss
( 4,565 )
( 4,565 )
Balance,
September 30,2019
33,720,044
$ 3
9,411
$ 94
-
$ -
$ 70,420
$ ( 72,725 )
$ ( 2,208 )
Common
Stock
Preferred
Stock
Common
Stock
Issuable
Additional
Paid In
Accumulated
Total
Stockholders’
Equity
Shares
Amount
Shares
Amount
Shares
Amount
Capital
Deficit
(Deficit)
Balance,
December 31, 2018
25,729,461
$ 3
9,411
$ 94
-
$ -
$ 53,591
$ ( 60,431 )
$ ( 6,743 )
Fair
value of vested options
1,077
1,077
Shares
granted to Directors for services
33,796
-
-
-
-
115
115
Fair
value of vested restricted shares granted to an officer for services
-
-
405
405
Dividends
on Series A Convertible Preferred Stock
-
-
-
-
( 5 )
( 5 )
Common
shares issued pursuant to the rights offering, net of offering costs
7,733,750
-
-
-
14,867
-
14,867
Exercise
of warrants
223,037
365
365
Net
Loss
-
( 12,289 )
( 12,289 )
Balance,
September 30, 2019
33,720,044
$ 3
9,411
$ 94
-
$ -
$ 70,420
$ ( 72,725 )
$ ( 2,208 )
The
accompanying notes are an integral part of these condensed financial statements.
F- 3
REED’S,
INC.
CONDENSED
STATEMENTS OF CASH FLOWS
For
the Nine months Ended September 30, 2020 and 2019
(Unaudited)
(Amounts
in thousands)
September
30, 2020
September
30, 2019
Cash
flows from operating activities:
Net
loss
$ ( 6,920 )
$ ( 12,289 )
Adjustments
to reconcile net loss to net cash used in operating activities:
Depreciation
56
12
(Gain)/loss
on sale of property & equipment
-
( 30 )
(Gain)/loss
on termination of leases
( 6 )
2
Amortization
of debt discount
290
225
Amortization
of right of use assets
89
96
Fair
value of vested options
722
1,077
Fair
value of vested restricted shares granted to officers
285
520
Decrease
in allowance for doubtful accounts
( 181 )
( 400 )
Decrease
(increase) in inventory reserve
( 422 )
325
Change
in fair value of warrant liability
( 1 )
( 23 )
Accrual
of interest on convertible note to a related party
439
390
Lease
liability
( 18 )
( 10 )
Changes
in operating assets and liabilities:
Accounts
receivable
( 2,367 )
( 1,121 )
Inventory
1,495
( 2,520 )
Prepaid
expenses and other assets
( 318 )
( 339 )
Accounts
payable
( 100 )
( 196 )
Accrued
expenses
189
( 347 )
Net
cash used in operating activities
( 6,768 )
( 14,628 )
Cash
flows from investing activities:
Trademark
costs
( 37 )
-
Proceeds
from sale of property and equipment
-
30
Purchase
of property and equipment
( 121 )
( 273 )
Net
cash used in investing activities
( 158 )
( 243 )
Cash
flows from financing activities:
Borrowings
on line of credit
34,645
42,179
Repayments
of line of credit
( 33,710 )
( 42,175 )
Capitalization
of financing costs
( 130 )
( 130 )
Proceeds
from note payable
770
-
Repayment
of amounts due to/from officers
-
195
Principal
repayments on capital lease obligation
( 11 )
( 38 )
Exercise
of options
14
-
Exercise
of warrants
-
365
Proceeds
from sale of common stock
5,310
14,867
Net
cash provided by financing activities
6,888
15,263
Net
increase in cash
( 38 )
392
Cash
at beginning of period
913
624
Cash
at end of period
$ 875
$ 1,016
Supplemental
disclosures of cash flow information:
Cash
paid for interest
$ 231
$ 408
Non
Cash Investing and Financing Activities
Dividends
on Series A Convertible Preferred Stock
$ 5
$ 5
The
accompanying notes are an integral part of these condensed financial statements.
F- 4
REED’S,
INC.
NOTES
TO CONDENSED FINANCIAL STATEMENTS
Three
and Nine months Ended September 30, 2020 and 2019 (Unaudited)
(In
thousands, except share and per share amounts)
1.
Basis of Presentation and Liquidity
The
accompanying interim condensed financial statements of Reed’s, Inc. (the “Company”, “we”, “us”,
or “our”), are unaudited, but in the opinion of management contain all adjustments, including normal recurring adjustments,
necessary to present fairly our financial position at September 30, 2020, the results of operations for the three and nine months
ended September 30, 2020 and 2019, and cash flows for the nine months ended September 30, 2020 and 2019. The balance sheet as
of December 31, 2019 is derived from the Company’s audited financial statements.
Certain
information and footnote disclosures normally included in financial statements that have been prepared in accordance with accounting
principles generally accepted in the United States of America have been condensed or omitted pursuant to the rules and regulations
of the Securities and Exchange Commission regarding interim financial reporting. We believe that the disclosures contained in
these condensed financial statements are adequate to make the information presented herein not misleading. For further information,
refer to the financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2019, as filed with the Securities and Exchange Commission on March 18, 2020 and amended on April 8, 2020.
The
results of operations for the nine months ended September 30, 2020 are not necessarily indicative of the results of operations
to be expected for the full fiscal year ending December 31, 2020.
COVID-19
Considerations
In
the quarter ended September 30, 2020, the COVID-19 pandemic did not have a material net impact on our operating results. In the
future, the pandemic may cause reduced demand for our products if, for example, the pandemic results in a recessionary economic
environment which negatively effects the consumers who purchase our products. Based on the recent increase in demand for our products,
we believe that over the long term, there will continue to be strong demand for our products.
Our
ability to operate without significant negative operational impact from the COVID-19 pandemic will in part depend on our ability
to protect our employees and our supply chain. The Company has endeavored to follow the recommended actions of government and
health authorities to protect our employees. For the six months ended September 30, 2020, we maintained the consistency of our
operations during the onset of the COVID-19 pandemic. We will continue to innovate in managing our business, coordinating with
our employees and suppliers to do our part in the infection prevention and remain flexible in responding to our customers and
suppliers. However, the uncertainty resulting from the pandemic could result in an unforeseen disruption to our workforce and
supply chain (for example an inability of a key supplier or transportation supplier to source and transport materials) that could
negatively impact our operations.
Through
September 30, 2020, the COVID-19 pandemic has not negatively impacted the Company’s liquidity position as of such date.
Shipments to customers in the third quarter of 2020 were up 14% from the first quarter of 2020, and down slightly (2%) from the
second quarter of 2020 with fluctuations consistent with historical seasonal patterns. Through September 30, 2020, we continue
to generate cash flows to meet our short-term liquidity needs, and we expect to maintain access to the capital markets. We have
also not observed any material impairments of our assets or a significant change in the fair value of our assets due to the COVID-19
pandemic.
For
additional information on risk factors related to the pandemic or other risks that could impact our results, please refer to “Risk
Factors” in Part II, Item 1A of this Form 10-Q.
F- 5
Liquidity
The
accompanying financial statements have been prepared under the assumption that the Company will continue as a going concern. Such
assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business.
For
the nine months ended September 30, 2020, the Company recorded a net loss of $ 6,920
and used cash in operations of $ 6,768 .
As of September 30, 2020, we had a cash balance of $ 875
with borrowing capacity of $ 3,037 ,
a stockholder’s equity of $ 558 and
a negative working capital of $ 207 ,
compared to a cash balance of $ 913
with borrowing capacity of $ 3,235 ,
stockholders’ equity of $ 1,147
and a working capital of $ 4,885
at December 31, 2019.
Historically,
we have financed our operations through public and private sales of common stock, issuance of preferred and common stock, convertible
debt instruments, term loans and credit lines from financial institutions, and cash generated from operations. We have taken decisive
action to improve our margins, including fully outsourcing our manufacturing process, streamlining our product portfolio, negotiating
improved vendor contracts, and restructuring our selling prices.
2.
Significant Accounting Policies
Use
of estimates
The
preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at
the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results
could differ from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory
obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible
assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments
issued for services.
Revenue
Recognition
The
Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers
(“ASC 606”). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services
to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment
when considering the terms of contract(s), which include (1) identifying the contract or agreement with a customer, (2) identifying
our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction
price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied.
The
Company does not have any significant contracts with customers requiring performance beyond delivery, and contracts with customers
contain no incentives or discounts that could cause revenue to be allocated or adjusted over time. Shipping and handling activities
are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised
service to the customer. Revenue and costs of sales are recognized when control of the products transfers to our customer, which
generally occurs upon shipment from our facilities. The Company’s performance obligations are satisfied at that time.
All
of the Company’s products are offered for sale as finished goods only, and there are no performance obligations required
post-shipment for customers to derive the expected value from them.
The
Company does not allow for returns, except for damaged products when the damage occurred pre-fulfillment. Damaged product returns
have historically been insignificant. Because of this, the stand-alone nature of our products, and our assessment of performance
obligations and transaction pricing for our sales contracts, we do not currently maintain a contract asset or liability balance
for obligations. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.
F- 6
Loss
per Common Share
Basic
earnings (loss) per share is computed by dividing the net income (loss) applicable to common stockholders by the weighted average
number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed by dividing the
net income applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional
common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock
method. Potential common shares are excluded from the computation when their effect is antidilutive.
For
the periods ended September 30, 2020 and 2019, the calculations of basic and diluted loss per share are the same because potential
dilutive securities would have had an anti-dilutive effect. The potentially dilutive securities consisted of the following:
Schedule of Potentially Dilutive Securities
September
30, 2020
September
30, 2019
Convertible
note to a related party
2,266,667
2,266,667
Warrants
6,413,782
6,413,782
Common
stock equivalent of Series A Convertible Preferred stock
37,644
37,644
Common
stock issuable
350,000
-
Unvested
restricted common stock
244,740
610,609
Options
4,716,357
4,373,566
Total
14,029,190
13,702,268
The
Series A Convertible Preferred Stock is convertible into Common shares at the rate of 1:4.
Stock
Compensation Expense
The
Company periodically issues stock options and restricted stock awards to employees and non-employees in non-capital raising transactions
for services and for financing costs. The Company accounts for such grants issued and vesting based on ASC 718, Compensation-Stock
Compensation whereby the value of the award is measured on the date of grant and recognized as compensation expense on the
straight-line basis over the vesting period. The Company recognizes the fair value of stock-based compensation within its Statements
of Operations with classification depending on the nature of the services rendered.
The
fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing model, which uses certain
assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock,
and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing
model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect
compensation expense recorded in future periods.
Advertising
Costs
Advertising
costs are expensed as incurred and are included in selling and marketing expense. Advertising costs for the three months ended
September 30, 2020 and 2019, aggregated $ 536 and $ 661 , respectively. Advertising costs for the nine months ended September 30,
2020 and 2019, aggregated $ 1,141 and $ 2,194 , respectively.
Concentrations
Sales.
During the three months ended September 30, 2020, two customers accounted for 24 % and 12 % of gross sales, respectively, and
during the nine months ended September 30, 2020, two customers accounted for 25 % and 13 % of gross sales, respectively. During
the three months ended September 30, 2019, the Company’s largest two customers accounted for 15 % and 12 % of gross sales,
respectively. During the nine months ended September 30, 2019, these customers accounted for 23 % and 13 % of gross sales, respectively.
No other customers exceeded 10 % of sales in either period.
F- 7
Accounts
receivable. As of September 30, 2020, the Company had accounts receivable from one customer which comprised 23 % of its gross
accounts receivable. As of December 31, 2019, the Company had accounts receivable from one customer which comprised 14 % of its
gross accounts receivable. No other customer exceeded 10 % of accounts receivable in either period.
Purchases
from vendors. During the three months ended September 30, 2020, two vendors accounted for 13 % and 11 % of all purchases. During
the nine months ended September 30, 2020, two vendors accounted for 11 % and 11 % of all purchases. During the three months ended
September 30, 2019, the Company’s largest three vendors accounted for approximately 13 %, 11 % and 10 % of all purchases, respectively.
During the nine months ended September 30, 2019, two vendors accounted for 12 % and 10 % of all purchases, respectively. No other
vendors exceeded 10 % of all purchases in either period.
Accounts
payable. As of September 30, 2020, of the Company’s two largest vendors, each accounted for 18 % and 11 % of the total
accounts payable. As of December 31, 2019, of the Company’s three largest vendors, accounted for 19 %, 15 %, and 14 % of the
total accounts payable. No other vendors exceeded 10 % of accounts payable in either period.
Fair
Value of Financial Instruments
The
Company uses various inputs in determining the fair value of its financial assets and liabilities and measures these assets on
a recurring basis. Financial assets recorded at fair value are categorized by the level of subjectivity associated with the inputs
used to measure their fair value. ASC 820 defines the following levels of subjectivity associated with the inputs:
Level
1—Quoted prices in active markets for identical assets or liabilities.
Level
2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.
Level
3—Unobservable inputs based on the Company’s assumptions.
The
carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts receivable, short-term bank
loans, accounts payable, notes payable and other payables, approximate their fair values because of the short maturity of these
instruments. The carrying values of capital lease obligations and long-term financing obligations approximate their fair values
because interest rates on these obligations are based on prevailing market interest rates.
As
of September 30, 2020, and December 31, 2019, the Company’s balance sheets included Level 2 liabilities comprised of the
fair value of warrant liabilities aggregating $ 7 and $ 8 , respectively (see Note 10).
Recent
Accounting Pronouncements
In
June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments . ASU 2016-13 requires entities
to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain
types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses.
ASU 2016-13 is effective for the Company beginning January 1, 2023, and early adoption is permitted. The Company does not believe
the potential impact of the new guidance and related codification improvements will be material to its financial position, results
of operations and cash flows.
F- 8
In
August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “ Debt—Debt with Conversion and Other Options
(Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible
Instruments and Contracts in an Entity’s Own Equity .” ASU 2020-06 will simplify the accounting for convertible
instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting
the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as
compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded
conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and
that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial
premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope
exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06
will be effective for the Company January 1, 2024. Early adoption is permitted, but no earlier than January 1, 2021, including
interim periods within that year. Management is currently evaluating the effect of the adoption of ASU 2020-06 on the consolidated
financial statements, but currently does not believe ASU 2020-06 will have a significant impact on the Company’s accounting
for its convertible debt instruments. The effect will largely depend on the composition and terms of the financial instruments
at the time of adoption.
Other
recent accounting pronouncements issued by the FASB, its Emerging Issues Task Force, the American Institute of Certified Public
Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on
the Company’s present or future financial statements.
3.
Inventory
Inventory
is valued at the lower of cost (first-in, first-out) or net realizable value, and net of reserves is comprised of the following
(in thousands):
Schedule of Inventory
September
30,
2020
December
31,
2019
Raw
materials and packaging
$ 6,354
$ 4,261
Finished
products
3,082
6,247
Total
$ 9,436
$ 10,508
The
Company has recorded a reserve for slow moving and potentially obsolete inventory. The reserve at September 30, 2020, and December
31, 2019, was $ 224
and $ 646 ,
respectively.
4.
Property and Equipment
Property
and equipment is comprised of the following (in thousands):
Schedule of Property and Equipment
September
30,
2020
December
31,
2019
Right-of-use
assets under operating leases
$ 730
$ 730
Right-of-use
assets under finance leases
67
179
Computer
hardware and software
400
543
Machinery
and equipment
103
83
Total
cost
1,300
1,535
Accumulated
depreciation and amortization
( 316 )
( 482 )
Net
book value
$ 984
$ 1,053
Depreciation
expense for the three months ended September 30, 2020 and 2019 was $ 35 and $ 8 , respectively. Depreciation expense for the nine
months ended September 30, 2020 and 2019 was $ 56 and $ 12 , respectively. During the nine months ended September 30, 2020, the Company
disposed of right-of-use assets under finance leases with a net book value of $ 45 , and terminated $ 51 of related finance leases
(see Note 9), resulting in a gain on lease termination of $ 6 .
F- 9
Equipment
held for sale consists of the following (in thousands):
Schedule of Equipment Held for Sale
September
30,
2020
December
31,
2019
Equipment
held for sale
$ 163
$ 163
Reserve
( 96 )
( 96 )
Net
book value
$ 67
$ 67
The
balance as of September 30, 2020, and December 31, 2019, consists of residual manufacturing equipment, at estimated net realizable
value, which management anticipates selling during 2020.
5.
Intangible Assets
Intangible
assets are comprised of brand names acquired, specifically Virgil’s, and costs related to trademarks. They have been assigned
an indefinite life, as we currently anticipate that they will contribute cash flows to the Company perpetually. These indefinite-lived
intangible assets are not amortized but are assessed for impairment annually and evaluated annually to determine whether the indefinite
useful life remains appropriate. We first assess qualitative factors to determine whether it is more likely than not that the
asset is impaired. If further testing is necessary, we compare the estimated fair value of our asset with its book value. If the
carrying amount of the asset exceeds its fair value, as determined by the discounted cash flows expected to be generated by the
asset, an impairment loss is recognized in an amount equal to that excess. Based on management’s measurement, there were
no indications of impairment at September 30, 2020.
Intangible
assets consist of the following (in thousands):
Summary of Intangible Assets
September
30,
2020
December
31,
2019
Brand
names
$ 576
$ 576
Trademarks
37
-
Total
$ 613
$ 576
6.
Line of Credit
Amounts
outstanding under the Company’s credit facilities are as follows (in thousands):
Schedule of Amount Outstanding Under Credit Facilities
September
30,
2020
December
31,
2019
Line
of Credit
$ 4,596
$ 3,661
Capitalized
finance costs
( 324 )
( 484 )
Net
balance
$ 4,272
$ 3,177
On
October 4, 2018, the Company entered into a financing agreement with Rosenthal & Rosenthal, Inc. The financing agreement provides
a maximum borrowing capacity of $ 13,000 . Borrowings are based on a formula of eligible accounts receivable and inventories (the
“permitted borrowings”) plus advances (an “over-advance” of up to $ 4,000 ) in excess of permitted borrowings.
At September 30, 2020, the unused borrowing capacity under the financing agreement was $ 3,037 . The line of credit matures on March
30, 2021 .
Borrowings
under the Rosenthal financing agreement bear interest at the greater of prime or 4.75 %, plus an additional 2.0 % to 3.5 % depending
on whether the borrowing is based upon receivables, inventory or is an over-advance. The effective interest rate as of September
30, 2020 on outstanding borrowings was 7.2 %. Additionally, the line of credit is subject to monthly facility and administration
fees, and aggregate minimum monthly fees (including interest) of $ 4 .
F- 10
The
line of credit is secured by substantially all of the assets excluding intellectual property of the Company. The over-advance
is secured by all of Reed’s intellectual property collateral. Additionally, any over-advance is guaranteed by an irrevocable
stand-by letter of credit in the amount of $ 1,500 ,
issued by Daniel J. Doherty III and the Daniel J. Doherty, III 2002 Family Trust, affiliates of Raptor/Harbor Reeds SPV LLC (“Raptor”).
As of September 30, 2020, Raptor beneficially owns 11.5 %
of the Company’s outstanding common stock and Mr. Doherty
is a member of the Company’s Board of Directors. In the event of a default under the financing agreement, Raptor has a put
option to purchase from Rosenthal the entire amount of any outstanding over-advance plus accrued interest, prior to Rosenthal
declaring an event of default under the financing agreement.
The
financing agreement with Rosenthal includes customary restrictions that limit our ability to engage in certain types of transactions,
including our ability to utilize tangible and intangible assets as collateral for other indebtedness. Additionally, the agreement
contains a financial covenant that requires us to meet certain minimum working capital and tangible net worth thresholds as of
the end of each quarter. We were in compliance with the terms of our agreement with Rosenthal as of September 30, 2020.
The
Company annually incurs an additional $ 130 of fees from the bank, which is equal to 1 % of the $13,000 borrowing limit. These costs
have been capitalized and recorded as a debt discount and are amortized over the remaining life of the Rosenthal agreement. The
2020 fee will be amortized over 0.5 years and the 2019 fee is being amortized over 1.5 years. Amortization of debt discount was
$ 290 and $ 225 for the nine months ended September 30, 2020 and 2019, respectively.
7.
Convertible Note to a Related Party
The
Convertible Note to a Related Party consists of the following (in thousands):
Schedule of Convertible Notes
September
30,
2020
December
31,
2019
12%
Convertible Note Payable
$ 3,400
$ 3,400
Accrued
Interest
1,728
1,289
Total
obligation
$ 5,128
$ 4,689
On
April 21, 2017, the Company issued a secured, convertible, subordinated, non-redeemable note in the principal amount of $ 3,400
and warrants to purchase 1,416,667
shares of common stock to Raptor. Raptor
beneficially owned approximately 11.5 %
and 14.9 %
of the Company’s common stock at September 30, 2020 and December 31, 2019, respectively.
The
Raptor Note bears interest at a rate of 12 % per annum, compounded monthly, and is secured by the Company’s assets, subordinate
to the first priority security interest of Rosenthal & Rosenthal (see Note 6). The note may not be prepaid and matures on
April 21, 2021 . It may be converted, at any time and from time to time, into shares of common stock of the Company, at a revised
conversion price of $ 1.50 .
The
warrants expire on April 21, 2022 and have an adjusted exercise price of $ 1.50 per share. The note and warrants contain customary
anti-dilution provisions, and the shares of common stock issuable upon conversion of the note and exercise of the warrants have
been registered on Form S-3.
8.
Note Payable
On
April 20, 2020, the Company was granted a loan (the “PPP loan”) from City National Bank in the aggregate amount of
$ 770 , pursuant to the Paycheck Protection Program (the “PPP”) under the CARES Act.
The
PPP loan agreement is dated April 20, 2020, matures on April 20, 2022 , bears interest at a rate of 1 % per annum, with the first
six months of interest deferred, is payable monthly commencing on November 2020, and is unsecured and guaranteed by the U.S. Small
Business Administration. The loan term may be extended to April 20, 2025, if mutually agreed to by the Company and lender. We
applied ASC 470, Debt , to account for the PPP loan. The PPP loan may be prepaid at any time prior to maturity with no prepayment
penalties. Funds from the PPP loan may only be used for qualifying expenses as described in the CARES Act, including qualifying
payroll costs, qualifying group health care benefits, qualifying rent and debt obligations, and qualifying utilities. The Company
intends to use the entire loan amount for qualifying expenses. Under the terms of the PPP, certain amounts of the loan may be
forgiven if they are used for qualifying expenses. The Company intends to apply for forgiveness of the PPP loan with respect to
these qualifying expenses, however, we cannot assure that such forgiveness of any portion of the PPP loan will occur. As for the
potential loan forgiveness, once the PPP loan is, in part or wholly, forgiven and a legal release is received, the liability would
be reduced by the amount forgiven and a gain on extinguishment would be recorded. The terms of the PPP loan provide for customary
events of default including, among other things, payment defaults, breach of representations and warranties, and insolvency events.
The Company was in compliance with the terms of the PPP loan as of September 30, 2020. At September 30, 2020, the note payable
balance was $ 770 , of which $ 470 were reflected as the current portion of note payable.
F- 11
9.
Leases Payable
The
Company adopted ASC 842, Leases , effective October 1, 2018. The standard requires a lessee to record a right-of-use asset
and a corresponding lease liability at the inception of the lease, initially measured at the present value of the lease payments.
The Company leases its headquarters office ,
and certain office equipment and automobiles. The Company analyzes all leases at inception to determine if a right-of-use asset
and lease liability should be recognized. Leases with an initial term of 12 months or less are not included on the condensed consolidated
balance sheets. The lease liability is measured at the present value of future lease payments as of the lease commencement date.
ASC
842 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated
over the lease term, generally on a straight-line basis.
During
the three and nine months ended September 30, 2020 and 2019, lease costs totaled $ 45
and $ 51 ,
and $ 135 and
$ 134 ,
respectively.
As
of December 31, 2019, the Company’s lease liabilities totaled $ 786 , made up of finance lease liabilities of $ 89 and operating
lease liabilities of $ 697 . During the nine months ended September 30, 2020, the Company terminated $ 51 of finance leases, and
made payments of $ 11 towards finance lease liability and $ 18 towards operating lease liability. As of September 30, 2020, lease
liabilities totaled $ 706, made up of finance lease liabilities of $ 27 and operating lease liabilities of $ 679.
As
of September 30, 2020, the weighted average remaining lease terms for operating lease and finance lease are 4.25 years and 0.39
years, respectively. As of September 30, 2020, the weighted average discount rate for operating lease is 12.6 % and 10.39 % for
finance lease.
Future
minimum lease payments under the leases are as follows (in thousands):
Schedule of Future Minimum Lease Payments
Years
Ending December 31,
Sep, 30
Remainder
of 2020
$ 67
2021
221
2022
222
2023
226
2024
221
Total
payments
957
Less:
Amount representing interest
( 251 )
Present
value of net minimum lease payments
706
Less:
Current portion
( 114 )
Non-current
portion
$ 592
10.
Warrant Liability
Various
sales of common stock made by the Company to finance operations have been accompanied by the issuance of warrants. Some of these
warrant agreements contain fundamental transaction provisions which may give rise to an obligation of the Company to pay cash
to the warrant holders. For accounting purposes, in accordance with ASC 480, Distinguishing Liabilities from Equity , those
warrants with fundamental transaction terms are accounted for as liabilities given the terms may give rise to an obligation of
the Company to the warrant holders. These liabilities are measured at fair value at each reporting period and the change in the
fair value is recognized in earnings in the accompanying Statements of Operations.
F- 12
The
fair value of the warrant liability was determined using the Black-Scholes-Merton option pricing model at September 30, 2020 and
December 31, 2019, using the following assumptions:
Schedule of Warrant Liability Using Assumptions
September
30,
2020
December
31,
2019
Stock
Price
$ 0.93
$ 0.91
Risk
free interest rate
0.80 %
1.95 %
Expected
volatility
119.51 %
83.36 %
Expected
life in years
0.67
1.42
Expected
dividend yield
0 %
0 %
Number
of Warrants containing fundamental transaction provisions
138,762
138,762
Fair Value
of Warrants
$ 7
$ 8
The
risk-free interest rate is based on rates established by the Federal Reserve Bank. The Company uses the historical volatility
of its common stock to estimate its future volatility. The expected life of the warrant is based upon its remaining contractual
life. The expected dividend yield reflects that the Company has not paid dividends to its common stockholders in the past and
does not expect to do so in the foreseeable future.
The
following table sets forth a summary of the changes in the estimated fair value of the warrant liability during the nine months
ended September 30, 2020 and 2019:
Schedule of Warrant Liability
September
30,
2020
September
30,
2019
Beginning
Balance
$ 8
$ 38
Change
in fair value
( 1 )
( 23 )
Ending
balance
$ 7
$ 15
11.
Stockholders’ Equity
Series
A Convertible Preferred Stock
On
July 2, 2020, the Company paid dividends on the Preferred Stock through the issuance of 4,530 of its common stock. The aggregate
fair value of the common stock issued was $ 5 based on an average market price of $ 1.04 per share.
Common
stock issuance
In
April 2020, the Company conducted a public offering of 15,333,334 shares of its common shares at a public offering price of $ 0.375
per share. The net proceeds to the Company from this offering are $ 5,310 , after deducting underwriting discounts and commissions
and other offering expenses. Proceeds from the offering will provide capital for working capital, and general corporate purposes.
During
the nine months ended September 30, 2020, the Company received proceeds of $ 14 , and issued 27,500 shares of common stock, on the
exercise of stock options.
F- 13
12.
Share-based payments
Restricted
common stock
The
following table summarizes restricted stock activity during the nine months ended September 30, 2020:
Summary
of Non-vested Restricted Stock Activity
Unvested
Shares
Issuable
Shares
Fair
Value
at Date of
Issuance
Weighted
Average
Grant Date
Fair Value
Balance, December
31, 2019
-
-
$ -
-
Granted
594,740
-
508
0.85
Vested
( 350,000 )
350,000
( 285 )
-
Issued
-
-
-
-
Balance,
September 30, 2020
244,740
350,000
$ 223
$ 0.85
During
the nine months ended September 30, 2020, the Company issued 594,740 shares of restricted stock to a director and two executive
employees. 350,000 of these shares vested immediately, 94,740 shares will vest in increments of 47,370 each over a two month period
of October and November 2020, 75,000 shares will vest in increments of 18,750 each over four years from the date of grant, and
75,000 shares will vest over four years based on performance criteria determined by the Board of Directors or Compensation Committee.
Unvested shares remain subject to forfeiture if vesting conditions are not met. The aggregate fair value of the stock awards was
$ 508 based on the market price of our common stock price which ranged from $ 0.81 to $ 0.95 per share on the dates of grants and
is amortized as shares vest. The total fair value of restricted common stock vesting during the nine months ended September 30,
2020 and 2019 was $ 285 and $ 477 , respectively, and is included in general and administrative expenses in the accompanying statements
of operations. As of September 30, 2020, the amount of unvested compensation related to issuances of restricted common stock was
$ 223 , which will be recognized as an expense in future periods as the shares vest. When calculating basic loss per share, these
shares are included in weighted average common shares outstanding from the time they vest. When calculating diluted net income
per share, these shares are included in weighted average common shares outstanding as of their grant date.
Stock
options
Schedule of Stock Option Activity
The
following table summarizes stock option activity during the nine months ended September 30, 2020:
Shares
Weighted-
Average
Exercise Price
Weighted-
Average
Remaining
Contractual
Terms
(Years)
Aggregate
Intrinsic
Value
Outstanding
at December 31, 2019
3,265,580
$ 2.19
7.09
$ 6
Granted
2,067,800
$ 0.67
Exercised
( 34,500 )
$ 0.50
Unvested
forfeited or expired
( 394,480 )
$ 1.93
Vested
forfeited or expired
( 188,043 )
$ 4.20
Outstanding
at September 30, 2020
4,716,357
$ 1.48
8.17
$ 505
Exercisable
at September 30, 2020
2,169,690
$ 1.47
7.46
$ 338
During
the nine months ended September 30, 2020, the Company approved options exercisable into 2,067,800 shares to be issued pursuant
to Reed’s 2017 Incentive Compensation Plan. 1,732,800 options were issued to employees including 582,800 options that vested
immediately, 575,000 options vesting annually over a four-year vesting period , and 575,000 options that will vest based on performance
criteria to be established by the board. In addition, 335,000 options granted to consultants, board members, and former employees
vest over various periods.
F- 14
The
stock options are exercisable at a price ranging from $ 0.44 to $ 0.89 per share and expire in ten years . The total fair value of
these options at grant date was approximately $ 1,168 , which was determined using a Black-Scholes-Merton option pricing model with
the following average assumption: stock price ranging from $0.44 to $0.89 per share, expected term of seven years , volatility
of 120 %, dividend rate of 0 %, and risk-free interest rate ranging from 0.56 % to 1.63 %. The expected term represents the weighted-average
period of time that share option awards granted are expected to be outstanding giving consideration to vesting schedules and historical
participant exercise behavior; the expected volatility is based upon historical volatility of the Company’s common stock;
the expected dividend yield is based on the fact that the Company has not paid dividends in the past and does not expect to pay
dividends in the future; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement
corresponding with the expected term of the share option award. The fair value of the options of $1,168 will be amortized as the
options vest in future periods through May 20, 2024 .
During
the nine months ended September 30, 2020 and 2019, the Company recognized $ 722 and $ 1,077 of compensation expense relating to
vested stock options. As of September 30, 2020, the aggregate amount of unvested compensation related to stock options was approximately
$ 1,594 which will be recorded as an expense in future periods as the options vest.
As
of September 30, 2020, the outstanding options have an intrinsic value of $ 338 . The aggregate intrinsic value was calculated as
the difference between the closing market price as of September 30, 2020, which was $ 0.93 , and the exercise price of the outstanding
stock options.
13.
Stock Warrants
As
of September 30, 2020, the Company has issued warrants to purchase an aggregate of 6,413,782 shares of common stock. The Company’s
warrant activity during the nine months ended September 30, 2020 is as follows:
Schedule
of Warrant Activity
Shares
Weighted-
Average
Exercise Price
Weighted-
Average
Remaining Contractual Terms (Years)
Aggregate
Intrinsic
Value
Outstanding
at December 31, 2019
6,413,782
$ 2.06
1.52
$ -
Exercised
-
-
Forfeited
or expired
-
-
Outstanding
at September 30, 2020
6,413,782
$ 2.06
0.77
$ -
Exercisable
at September 30, 2020
6,413,782
$ 2.06
0.77
$ -
There
were no warrant transactions during the nine months ended September 30, 2020. As of September 30, 2020, the outstanding warrants
have no intrinsic value. The intrinsic value was calculated as the difference between the closing market price as of September
30, 2020, which was $ 0.93 , and the exercise price of the Company’s warrants to purchase common stock.
14.
Related Party Activities
On
December 31, 2018, the Company completed the sale of its Los Angeles manufacturing plant to California Custom Beverage, LLC (“CCB”),
an entity owned by Christopher J. Reed, a related party, and CCB assumed the monthly payments on our lease obligation for the
Los Angeles manufacturing plant. Our release from the obligation by the lessor, however, is dependent upon CCB’s deposit
of $ 1,200 of security with the lessor. The deposit is secured by Mr. Reed’s pledge of common stock to the lessor and guaranteed
personally by Mr. Reed and his wife. As of September 30, 2020, $ 800 has been deposited with the lessor and Mr. Reed has placed
approximately 363,000 pledged shares valued at $ 338 that remain in escrow with the lessor.
Beginning
in 2019, we are to receive a 5 % royalty on CCB’s private label sales to existing customers for three years and a 5 % referral
fee on CCB’s private label sales to referred customers for three years. During the nine months ended September 30, 2020,
the Company recorded royalty revenue from CCB of $ 26 . During the nine months ended September 30, 2019, the Company recorded royalty
revenue from CCB of $ 14 .
At
December 31, 2019, the Company had royalty revenue receivable from CCB of $ 128 . In addition, at December 31, 2019, the Company
has outstanding receivable from CCB of $ 228 consisting of inventory advances to CCB. The aggregate receivable from CCB at December
31, 2019 was $ 356 . During the nine months ended September 30, 2020, the Company recorded additional royalty revenue receivable
of $ 26 , advance additional inventory and equipment of $ 138 , and received payments of $ 129 , leaving an aggregate receivable balance
of $ 391 at September 30, 2020.
At
September 30, 2020 and December 31, 2019, the Company had accounts payable due to CCB of $ 211 and $ 182 , respectively.
15.
Subsequent Events
Subsequent
to September 30, 2020, the Company issued 7,000 shares of common stock on the exercise of stock options.
F- 15
Item
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with our
financial statements and the related notes appearing elsewhere in this report. This discussion and analysis may contain forward-looking
statements based on assumptions about our future business.
Overview
During
the third quarter of 2020, the Company fully utilized their expanded network of co-packers and implemented an upgraded set of
quality protocols. In addition to our
traditional sales channels, the Company is utilizing their ecommerce platform that includes their branded web sites and Amazon
to offer its line of shots, ginger candy and drinks packaged in cans.
A
public equity offering, which closed on April 20, 2020, provided the Company with funds for working capital and general corporate
purposes. These funds enabled us to initiate the implementation of our 2020 strategy that included driving growth while
strategically reducing operating costs.
The
Company remains focused on driving sales growth and improving margin. The sales growth focus is on channel expansion, new product
introduction and improved sales execution. The margin enhancement initiative is driven by co-packer upgrades, better leveraged
purchasing and improved efficiency. Underpinning these initiatives is a focus on strategically reducing operating costs.
COVID-19
Considerations
In
the quarter ended September 30, 2020, the COVID-19 pandemic did not have a material net impact on our operating results. In the
future, the pandemic may cause reduced demand for our products if, for example, the pandemic results in a recessionary economic
environment which negatively effects the consumers who purchase our products. Based on the recent increase in demand for our products,
we believe that over the long term, there will continue to be strong demand for our products.
Our
ability to operate without significant negative operational impact from the COVID-19 pandemic will in part depend on our ability
to protect our employees and our supply chain. The Company has endeavored to comply with the recommended actions of government
and health authorities to protect our employees. For the six months ended September 30, 2020, we maintained the consistency of
our operations during the onset of the COVID-19 pandemic. We will continue to innovate in managing our business, coordinating
with our employees and suppliers to do our part in the infection prevention and remain flexible in responding to our customers
and suppliers. However, the uncertainty resulting from the pandemic could result in an unforeseen disruption to our workforce
and supply chain (for example an inability of a key supplier or transportation supplier to source and transport materials) that
could negatively impact our operations.
Through
September 30, 2020, in part due to our innovative response to the COVID-19 pandemic, the COVID-19 pandemic has not negatively
impacted the Company’s liquidity position as of such date. Shipments to customers in the third quarter were up 14% from
the first quarter of the year and down slightly (2%) from the Second quarter of 2020, with fluctuations consistent with historical
seasonal patterns. Through September 30, 2020, we continue to generate cash flows to meet our short-term liquidity needs,
and we expect to maintain access to the capital markets. We have also not observed any material impairments of our assets or a
significant change in the fair value of our assets due to the COVID-19 pandemic.
For
additional information on risk factors related to the pandemic or other risks that could impact our results, please refer to “Risk
Factors” in Part II, Item 1A of this Form 10-Q.
1
Results
of Operations – Three months ended September 30, 2020
The
following table sets forth key statistics for the three months ended September 30, 2020 and 2019, respectively, in thousands.
Three Months Ended September 30,
Pct.
2020
2019
Change
Gross sales (A)
$
11,897
$
10,112
18
%
Less: Promotional and other allowances (B)
1,335
1,372
-3
%
Net sales
$
10,562
$
8,740
21
%
Cost of goods produced (C)
7,176
6,238
15
%
% of Gross sales
60
%
62
%
% of Net sales
68
%
71
%
Gross profit
$
3,386
$
2,502
35
%
% of Net sales
32
%
29
%
Expenses
Delivery and handling
$
2,207
$
1,902
16
%
% of Net sales
21
%
22
%
Dollar per case ($)
3.5
3.5
Selling and marketing
1,872
2,508
-25
%
% of Net sales
18
%
29
%
General and administrative
1,583
2,470
-36
%
% of Net sales
15
%
28
%
Total Operating expenses
5,662
6,880
-18
%
Loss from operations
$
(2,276
)
$
(4,378
)
-45
%
Interest expense and other expense
(314
)
(187
)
68
%
Net loss
$
(2,590
)
$
(4,565
)
-43
%
Loss per share – basic and diluted
$
(0.04
)
$
(0.14
)
-70
%
Weighted average shares outstanding - basic & diluted
62,940,091
33,716,359
87
%
(A)
Gross sales are used internally by management as an indicator of and to monitor operating performance, including sales performance
of particular products, salesperson performance, product growth or declines and overall Company performance. The use of gross
sales allows evaluation of sales performance before the effect of any promotional items, which can mask certain performance issues.
We therefore believe that the presentation of gross sales provides a useful measure of our operating performance. Gross sales
are not a measure that is recognized under GAAP and should not be considered as an alternative to net sales, which is determined
in accordance with GAAP, and should not be used alone as an indicator of operating performance in place of net sales. Additionally,
gross sales may not be comparable to similarly titled measures used by other companies, as gross sales have been defined by our
internal reporting practices. In addition, gross sales may not be realized in the form of cash receipts as promotional payments
and allowances may be deducted from payments received from certain customers.
(B)
Although the expenditures described in this line item are determined in accordance with GAAP and meet GAAP requirements, the disclosure
thereof does not conform to GAAP presentation requirements. Additionally, our definition of promotional and other allowances may
not be comparable to similar items presented by other companies. Promotional and other allowances primarily include consideration
given to the Company’s distributors or retail customers including, but not limited to the following: (i) reimbursements
given to the Company’s distributors for agreed portions of their promotional spend with retailers, including slotting, shelf
space allowances and other fees for both new and existing products; (ii) the Company’s agreed share of fees given to distributors
and/or directly to retailers for in-store marketing and promotional activities; (iii) the Company’s agreed share of slotting,
shelf space allowances and other fees given directly to retailers; (iv) incentives given to the Company’s distributors and/or
retailers for achieving or exceeding certain predetermined sales goals; and (v) discounted or free products. The presentation
of promotional and other allowances facilitates an evaluation of their impact on the determination of net sales and the spending
levels incurred or correlated with such sales. Promotional and other allowances constitute a material portion of our marketing
activities. The Company’s promotional allowance programs with its numerous distributors and/or retailers are executed through
separate agreements in the ordinary course of business. These agreements generally provide for one or more of the arrangements
described above and are of varying durations, ranging from one week to one year.
2
(C)
Cost of goods produced: Cost of goods produced consists of the costs of raw materials and packaging utilized in the manufacture
of products, co-packing fees, repacking fees, in-bound freight charges, inventory adjustments, as well as certain internal transfer
costs. Cost of goods produced is used internally by management to measure the direct costs of goods sold, aside from unallocated
plant costs. Cost of goods produced is not a measure that is recognized under GAAP and should not be considered as an alternative
to cost of goods sold, which is determined in accordance with GAAP, and should not be used alone as an indicator of operating
performance in place of cost of goods sold.
Sales,
Cost of Sales, and Gross Margins
The
following chart sets forth key statistics for the transition of the Company’s top line activity through the third quarter
of 2020 and 2019.
2020
2019
Q3
Per Case
Sept
YTD Per Case
Q1
Q2
Q3
YTD
Q3
vs PY
YTD
vs PY
Q1
Q2
Q3
YTD
2020
2019
vs
PY
2020
2019
vs
PY
Cases:
Reed’s
288
335
314
937
32 %
24 %
238
281
238
757
Virgil’s
262
308
319
889
6 %
4 %
257
296
302
855
Total
Core
550
643
633
1,826
17 %
13 %
495
577
540
1,612
Non
Core
2
-
-
2
-95 %
-92 %
20
2
4
26
Candy
8
8
5
21
-10 %
-11 %
9
9
6
24
Total
560
651
639
1,850
16 %
11 %
524
588
550
1,662
Gross
Sales:
Core
$ 10,175
$ 11,940
$ 11,622
$ 33,737
18 %
15 %
$ 9,098
$ 10,455
$ 9,809
$ 29,362
$ 18.4
$ 18.2
1 %
$ 18.5
$ 18.2
1 %
Non
Core
102
33
74
209
-44 %
-39 %
181
29
131
341
$ 350.1
$ 32.8
969 %
94.4
13.1
619 %
Candy
274
256
201
731
17 %
6 %
241
274
172
687
$ 37.3
$ 28.7
30 %
34.2
28.6
19 %
Total
$ 10,551
$ 12,229
$ 11,897
$ 34,677
18 %
14 %
$ 9,520
$ 10,758
$ 10,112
$ 30,390
$ 18.6
$ 18.4
1 %
18.7
18.3
3 %
Discounts:
Total
$ (1,028 )
$ (1,376 )
$ (1,335 )
$ (3,739 )
-3 %
0 %
$ (1,071 )
$ (1,278 )
$ (1,372 )
$ (3,721 )
$ (2.1 )
$ (2.5 )
-16 %
$ (2.0 )
$ (2.2 )
-10 %
COGS:
Core
$ (6,414 )
$ (7,674 )
$ (7,031
)
$ (21,119 )
15 %
15 %
$ (5,469 )
$ (6,843 )
$ (6,094 )
$ (18,406 )
$ (11.1 )
$ (11.3 )
-2 %
$ (11.6 )
$ (11.1 )
4 %
Non
Core
(59 )
(15 )
(15 )
(89 )
-59 %
-62 %
(167 )
(28 )
(38 )
(233 )
(73.2 )
(9.5 )
672 %
(40.4 )
(9.0 )
351 %
Candy
(180 )
(176 )
(129 )
(485 )
22 %
10 %
(159 )
(177 )
(106 )
(442 )
(24.0 )
(17.6 )
36 %
(22.7 )
(18.4 )
23 %
Idle
Plant
-
--
-
-
-100 %
(150 )
(159 )
-
(309 )
-
-
0 %
-
(0.2 )
-100 %
Total
$ (6,653 )
$ (7,865 )
$ (7,176 )
$ (21,694 )
15 %
12 %
$ (5,945 )
$ (7,207 )
$ (6,238 )
$ (19,390 )
$ (11.2 )
$ (11.3 )
-2 %
$ (11.7 )
$ (11.7 )
0 %
Gross
Margin:
$ 2,870
$ 2,988
$ 3,386
$ 9,244
35 %
27 %
$ 2,504
$ 2,273
$ 2,502
$ 7,279
$ 5.3
$ 4.5
17 %
$ 5.0
$ 4.4
15 %
as
% Net Sales
30 %
28 %
32 %
30 %
30 %
24 %
29 %
27 %
As
part of the Company’s ongoing initiative to simplify and streamline operations by reducing the number of SKUs, the Company
has identified core products on which to place its strategic focus. These core products consist of Reed’s and Virgil’s
branded beverages. Beginning in 2020, our Wellness Shots are captured in Non-core products. Non-core products for 2019 consist
primarily of slower selling discontinued Reed’s and Virgil’s SKUs.
Sales
As
a result of our decision to focus on the core Reed’s and Virgil’s beverage brands and simplify operations by reducing
the overall number of SKUs that we offer, the Company’s core beverage volume for the quarter ended September 30, 2020, represents
98% of all beverage volume.
Core
brand gross revenue increased by 18% to $11,622 compared to the same period last year, driven by Reed’s volume growth of
32%. The result is an increase in total gross revenue of 18%, to $11,896 from $10,112 during the same period last year. Price
on our core brands increased $0.19 per case or 1% year over year, while volume grew 17% as compared to the same period last year.
3
Discounts
as a percentage of gross sales decreased to 11% in the third quarter of 2020 from 14% in the same period last year. As a result,
net sales revenue grew 21% in the third quarter of 2020 to $10,562, compared to $8,740 in the same period last year.
Cost
of Goods Sold and Produced
Cost of goods sold increased $938 during
the third quarter of 2020 as compared to the same period last year. As a percentage of net sales, cost of goods sold in the third
quarter of 2020 improved to 68% as compared to 71% for the same period last year.
The total cost of goods per case decreased
to $11.24 per case in the third quarter of 2020 from $11.34 per case for the same period last year. The cost of goods sold
per case on core brands was $11.11 during the third quarter of 2020, compared to $11.29 and the third quarter of 2019.
Gross Margin
Gross margin increased to 32% for the
third quarter of 2020, compared to 29% during the same period last year.
Operating
Expenses
Delivery
and Handling Expenses
Delivery
and handling expenses consist of delivery costs to customers and warehousing costs incurred for handling our finished goods after
production. Delivery and handling expenses increased by $306 in the third quarter of 2020 to $2,207 from $1,902 in the same period
last year, driven by increased volumes. Delivery costs in the third quarter of 2020 were 21% of net sales and $3.45 per case,
compared to 22% of net sales and $3.46 per case during the same period last year.
Selling
and Marketing Expenses
Marketing
expenses consist of direct marketing, marketing labor, and marketing support costs. Selling expenses consist of all other selling-related
expenses including personnel and contractor support.
Total
selling and marketing expenses were $1,872 during the third quarter of 2020, compared to $2,508 during the same period last year.
As a percentage of net sales, selling and marketing costs decreased to 18% during the third quarter of 2020, as compared to 29%
during the same period last year. The decrease represents a lapping of the “Fooled Your Mom” campaign in the third
quarter of 2019 and a lower level of digital advertising, event sampling and agency fees. In addition, personnel and travel related
costs declined.
General
and Administrative Expenses
General
and administrative expenses consist primarily of the cost of executive, administrative, and finance personnel, as well as professional
fees. General and administrative expenses decreased in the third quarter of 2020 to $1,583 from $2,470, a decrease of $887 over
the same period last year. Decrease was driven by a $643 decrease in severance expense, $214 decrease in stock option expense,
and a $74 decrease in professional and consulting fees, partially offset by a $44 increase in other general and administrative
expenses.
Loss
from Operations
The loss from operations was $2,276
for the third quarter of 2020, as compared to a loss of $4,378 in the same period last year driven by increase gross profit and
reductions in operating expenses discussed above.
4
Interest
and Other Expense
Interest
and other expense for the third quarter of 2020, consisted of $322 of interest expense offset by the change in fair value of our
warrant liability of $8. During the same period last year, interest and other expense consisted of $318 of interest expense offset
by the change in fair value of our warrant liability of $131.
Modified
EBITDA
In
addition to our GAAP results, we present Modified EBITDA as a supplemental measure of our performance. However, Modified EBITDA
is not a recognized measurement under GAAP and should not be considered as an alternative to net income, income from operations
or any other performance measure derived in accordance with GAAP, or as an alternative to cash flow from operating activities
as a measure of liquidity. We define Modified EBITDA as net income (loss), plus interest expense, depreciation and amortization,
stock-based compensation, changes in fair value of warrant expense, and one-time restructuring-related costs including employee
severance and asset impairment.
Management
considers our core operating performance to be that which our managers can affect in any particular period through their management
of the resources that affect our underlying revenue and profit generating operations during that period. Non-GAAP adjustments
to our results prepared in accordance with GAAP are itemized below. You are encouraged to evaluate these adjustments and the reasons
we consider them appropriate for supplemental analysis. In evaluating Modified EBITDA, you should be aware that in the future
we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of Modified
EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items.
Set
forth below is a reconciliation of net loss to Modified EBITDA for the three months ended September 30, 2020 and 2019 (unaudited;
in thousands):
Three
Months Ended September 30,
2020
2019
Net
loss
$ (2,590 )
$ (4,565 )
Modified
EBITDA adjustments:
Depreciation
and amortization
59
38
Interest
expense
322
318
Stock
option and other noncash compensation
263
368
Change
in fair value of warrant liability
(8 )
(131 )
Severance
-
643
Total
EBITDA adjustments
$ 636
$ 1,236
Modified
EBITDA
$ (1,954 )
$ (3,329 )
We
present Modified EBITDA because we believe it assists investors and analysts in comparing our performance across reporting periods
on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. In addition,
we use Modified EBITDA in developing our internal budgets, forecasts and strategic plan; in analyzing the effectiveness of our
business strategies in evaluating potential acquisitions; making compensation decisions; and in communications with our board
of directors concerning our financial performance. Modified EBITDA has limitations as an analytical tool, which includes, among
others, the following:
●
Modified
EBITDA does not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments;
●
Modified
EBITDA does not reflect changes in, or cash requirements for, our working capital needs;
●
Modified
EBITDA does not reflect future interest expense, or the cash requirements necessary to service interest or principal payments,
on our debts; and
●
Although
depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced
in the future, and Modified EBITDA does not reflect any cash requirements for such replacements.
5
Results
of Operations – Nine months ended September 30, 2020
The
following table sets forth key statistics for the nine months ended September 30, 2020 and 2019, respectively, in thousands.
Nine Months Ended September 30,
Pct.
2020
2019
Change
Gross sales (A)
$
34,677
$
30,391
14
%
Less: Promotional and other allowances (B)
3,739
3,721
-
%
Net sales
$
30,938
$
26,669
16
%
Cost of goods produced (C)
21,694
19,081
14
%
% of Gross sales
63
%
63
%
% of Net sales
70
%
72
%
Cost of goods sold – idle capacity (D)
-
309
-100
%
% of Net sales
-
%
1
%
Gross profit
$
9,244
$
7,279
27
%
% of Net sales
30
%
27
%
Expenses
Delivery and handling
$
4,950
$
4,369
13
%
% of Net sales
16
%
16
%
Dollar per case ($)
2.7
2.6
Selling and marketing
5,382
7,718
-30
%
% of Net sales
17
%
29
%
General and administrative
4,872
6,557
-26
%
% of Net sales
16
%
25
%
Total Operating expenses
15,204
18,644
-18
%
Loss from operations
$
(5,960
)
$
(11,365
)
-48
%
Interest expense and other expense
(960
)
(924
)
4
%
Net loss
$
(6,920
)
$
(12,289
)
-44
%
Loss per share – basic and diluted
$
(0.12
)
$
(0.38
)
-68
%
Weighted average shares outstanding - basic & diluted
56,706,141
32,179,119
76
%
6
(A)
Gross sales are used internally by management as an indicator of and to monitor operating performance, including sales performance
of particular products, salesperson performance, product growth or declines and overall Company performance. The use of gross
sales allows evaluation of sales performance before the effect of any promotional items, which can mask certain performance issues.
We therefore believe that the presentation of gross sales provides a useful measure of our operating performance. Gross sales
are not a measure that is recognized under GAAP and should not be considered as an alternative to net sales, which is determined
in accordance with GAAP, and should not be used alone as an indicator of operating performance in place of net sales. Additionally,
gross sales may not be comparable to similarly titled measures used by other companies, as gross sales have been defined by our
internal reporting practices. In addition, gross sales may not be realized in the form of cash receipts as promotional payments
and allowances may be deducted from payments received from certain customers.
(B)
Although the expenditures described in this line item are determined in accordance with GAAP and meet GAAP requirements, the disclosure
thereof does not conform to GAAP presentation requirements. Additionally, our definition of promotional and other allowances may
not be comparable to similar items presented by other companies. Promotional and other allowances primarily include consideration
given to the Company’s distributors or retail customers including, but not limited to the following: (i) reimbursements
given to the Company’s distributors for agreed portions of their promotional spend with retailers, including slotting, shelf
space allowances and other fees for both new and existing products; (ii) the Company’s agreed share of fees given to distributors
and/or directly to retailers for in-store marketing and promotional activities; (iii) the Company’s agreed share of slotting,
shelf space allowances and other fees given directly to retailers; (iv) incentives given to the Company’s distributors and/or
retailers for achieving or exceeding certain predetermined sales goals; and (v) discounted or free products. The presentation
of promotional and other allowances facilitates an evaluation of their impact on the determination of net sales and the spending
levels incurred or correlated with such sales. Promotional and other allowances constitute a material portion of our marketing
activities. The Company’s promotional allowance programs with its numerous distributors and/or retailers are executed through
separate agreements in the ordinary course of business. These agreements generally provide for one or more of the arrangements
described above and are of varying durations, ranging from one week to one year.
(C)
Cost of goods produced: Cost of goods produced consists of the costs of raw materials and packaging utilized in the manufacture
of products, co-packing fees, repacking fees, in-bound freight charges, inventory adjustments, as well as certain internal transfer
costs. Cost of goods produced is used internally by management to measure the direct costs of goods sold, aside from unallocated
plant costs. Cost of goods produced is not a measure that is recognized under GAAP and should not be considered as an alternative
to cost of goods sold, which is determined in accordance with GAAP, and should not be used alone as an indicator of operating
performance in place of cost of goods sold.
(D)
Cost of goods sold – idle capacity: Cost of goods sold – idle capacity consists of direct production costs in excess
of charges allocated to our finished goods in production. Plant costs in excess of production allocations are expensed in the
period incurred rather than added to the cost of finished goods produced. Plant costs include labor costs, production supplies,
repairs and maintenance, and inventory write-off. Our charges for labor and overhead allocated to our finished goods are determined
on a market cost basis, which is lower than our actual costs incurred. Cost goods sold – idle capacity is not a measure
that is recognized under GAAP and should not be considered as an alternative to cost of goods sold, which is determined in accordance
with GAAP, and should not be used alone as an indicator of operating performance in place of cost of goods sold.
Sales,
Cost of Sales, and Gross Margins
As
part of the Company’s ongoing initiative to simplify and streamline operations by reducing the number of SKUs, the Company
has identified core products on which to place its strategic focus. These core products consist of Reed’s and Virgil’s
branded beverages. Beginning in 2020, our Wellness Shots are captured in Non-core products. Non-core products for 2019 consist
primarily of slower selling discontinued Reed’s and Virgil’s SKUs.
7
Sales
As
a result of our decision to focus on the core Reed’s and Virgil’s beverage brands and simplify operations by reducing
the overall number of SKUs that we offer, the Company’s core beverage volume for the first nine months of 2020, represents
98% of all beverage volume.
Core
brand gross revenue increased by 15% to $33,737 compared to the same period last year, driven by Reed’s volume growth of
24%. The result is an increase in total gross revenue of 14%, to $34,677 from $30,391 during the same period last year. Price
on our core brands increased $0.26 per case or 1% year over year, while volume grew 13% as compared to the same period last year.
Discounts
as a percentage of gross sales decreased to 11% in the first nine months of 2020 from 12% in the same period last year. The decrease
in our promotions was driven by lower promotional activity primarily due to the impacts of COVID-19 as promotional execution became
a lower priority at retail. As a result, net sales revenue grew 16% in the first nine months of 2020 to $30,938, compared to $26,669
in the same period last year.
Cost
of Goods Sold and Produced
Cost of goods sold increased $2,304
during the first nine months of 2020 as compared to the same period last year. As a percentage of net sales, cost of goods sold
in the first nine months of 2020 improved to 70% as compared to 73% for the same period last year.
The total cost of goods per case increased
to $11.73 per case in the first nine months of 2020 from $11.67 per case in the same period last year. The increase is
driven by utilization of higher costed inventory remaining from 2019 in the first quarter and a $198 reserve recorded related
to packaging material from transition to the FDA mandated nutritional fact requirements disclosure. The cost of goods sold per
case on core brands increased to $11.57 during the first nine months of 2020, from the $11.42 for the same period
last year. We are continuing to work with suppliers and co-packers to improve our processes and maximize cost efficiencies.
Gross
Margin
Gross
margin increased to 30% for the first nine months of 2020, compared to 27% during the same period last year.
Operating
Expenses
Delivery
and Handling Expenses
Delivery
and handling expenses consist of delivery costs to customers and warehousing costs incurred for handling our finished goods after
production. Delivery and handling expenses increased by $581 in the first nine months of 2020 to $4,950 from $4,369 in the same
period last year, driven by increased volumes. Delivery costs in the nine months of 2020 were 16% of net sales and $2.68 per case,
compared to 16% of net sales and $2.63 per case during the same period last year. The per case rate increase was driven by market
forces impacted by COVID-19.
Selling
and Marketing Expenses
Marketing
expenses consist of direct marketing, marketing labor, and marketing support costs. Selling expenses consist of all other selling-related
expenses including personnel and contractor support.
Total
selling and marketing expenses were $5,382 during the first nine months of 2020, compared to $7,718 during the same period last
year. As a percentage of net sales, selling and marketing costs decreased to 17% during the first nine months of 2020, as compared
to 29% during the same period last year. The decrease represents a lapping of the “Fooled Your Mom” campaign which
ran in the second quarter of 2019 as well as the Catalina retail register coupon program, which has yet to be used in 2020 and
a lower level of digital advertising, event sampling and agency fees. In addition, personnel and travel related costs declined.
8
General
and Administrative Expenses
General
and administrative expenses consist primarily of the cost of executive, administrative, and finance personnel, as well as professional
fees. General and administrative expenses decreased in the first nine months of 2020 to $4,872 from $6,557, a decrease of $1,685
over the same period last year. The decrease was driven by lower severance of $682, forfeiture/expiration of options in the amount
of $580, the lapping of a $220 one-time final transition cost incurred in 2019 related to our plant sale and a reduction professional
fees and consultants of $70, and lower personnel and travel related costs.
Loss
from Operations
The loss from operations was $5,960
for the first nine months of 2020, as compared to a loss of $11,365 in the same period last year driven by increase gross profit
and reductions in operating expenses discussed above.
Interest
and Other Expense
Interest
and other expense for the first nine months of 2020, consisted of $961 of interest expense offset by the change in fair value
of our warrant liability of $1. During the same period last year, interest and other expense consisted of $947 of interest expense
offset by the change in fair value of our warrant liability of $23.
Modified
EBITDA
In
addition to our GAAP results, we present Modified EBITDA as a supplemental measure of our performance. However, Modified EBITDA
is not a recognized measurement under GAAP and should not be considered as an alternative to net income, income from operations
or any other performance measure derived in accordance with GAAP, or as an alternative to cash flow from operating activities
as a measure of liquidity. We define Modified EBITDA as net income (loss), plus interest expense, depreciation and amortization,
stock-based compensation, changes in fair value of warrant expense, and one-time restructuring-related costs including employee
severance and asset impairment.
Management
considers our core operating performance to be that which our managers can affect in any particular period through their management
of the resources that affect our underlying revenue and profit generating operations during that period. Non-GAAP adjustments
to our results prepared in accordance with GAAP are itemized below. You are encouraged to evaluate these adjustments and the reasons
we consider them appropriate for supplemental analysis. In evaluating Modified EBITDA, you should be aware that in the future
we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of Modified
EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items.
Set
forth below is a reconciliation of net loss to Modified EBITDA for the nine months ended September 30, 2020 and 2019 (unaudited;
in thousands):
Nine Months Ended September 30,
2020
2019
Net loss
$
(6,920
)
$
(12,289
)
Modified EBITDA adjustments:
Depreciation and amortization
145
108
Interest expense
961
947
Stock option and other noncash compensation
1,007
1,597
Change in fair value of warrant liability
(1
)
(23
)
Severance
-
682
Total EBITDA adjustments
$
2,112
$
3,311
Modified EBITDA
$
(4,808
)
$
(8,978
)
9
We
present Modified EBITDA because we believe it assists investors and analysts in comparing our performance across reporting periods
on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. In addition,
we use Modified EBITDA in developing our internal budgets, forecasts and strategic plan; in analyzing the effectiveness of our
business strategies in evaluating potential acquisitions; making compensation decisions; and in communications with our board
of directors concerning our financial performance. Modified EBITDA has limitations as an analytical tool, which includes, among
others, the following:
●
Modified
EBITDA does not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments;
●
Modified
EBITDA does not reflect changes in, or cash requirements for, our working capital needs;
●
Modified
EBITDA does not reflect future interest expense, or the cash requirements necessary to service interest or principal payments,
on our debts; and
●
Although
depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced
in the future, and Modified EBITDA does not reflect any cash requirements for such replacements.
Liquidity
and Capital Resources
The
accompanying financial statements have been prepared under the assumption that the Company will continue as a going concern. Such
assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business.
For the nine months ended September 30, 2020,
the Company recorded a net loss of $6,920 and used cash in operations of $6,768. As of September 30, 2020, we had a cash
balance of $875 with borrowing capacity of $3,037, a stockholder’s equity of $558 and a negative working capital
of $207, compared to a cash balance of $913 with borrowing capacity of $3,235, stockholders’ equity of $1,147 and
a working capital of $4,885 at December 31, 2019.
In
April 2020, the Company conducted a public offering of 15,333,334 shares of its common stock at $0.375 per share, resulting in
net proceeds to the Company of $5,310.
On
April 20, 2020, the Company received loan proceeds in the amount of $770 pursuant to the Paycheck Protection Program under the
Coronavirus Aid, Relief and Economic Security Act (the “Cares Act”) (see Note 8).
The
PPP loan agreement is dated April 20, 2020, matures on April 20, 2022, bears interest at a rate of 1% per annum, with the first
six months of interest deferred, is payable monthly commencing on November 2020, and is unsecured and guaranteed by the U.S. Small
Business Administration. The loan term may be extended to April 20, 2025, if mutually agreed to by the Company and lender. We
applied ASC 470, Debt , to account for the PPP loan. The PPP loan may be prepaid at any time prior to maturity with no prepayment
penalties. Funds from the PPP loan may only be used for qualifying expenses as described in the CARES Act, including qualifying
payroll costs, qualifying group health care benefits, qualifying rent and debt obligations, and qualifying utilities. The Company
intends to use the entire loan amount for qualifying expenses. Under the terms of the PPP, certain amounts of the loan may be
forgiven if they are used for qualifying expenses. The Company intends to apply for forgiveness of the PPP loan with respect to
these qualifying expenses, however, we cannot assure that such forgiveness of any portion of the PPP loan will occur. As for the
potential loan forgiveness, once the PPP loan is, in part or wholly, forgiven and a legal release is received, the liability would
be reduced by the amount forgiven and a gain on extinguishment would be recorded. The terms of the PPP loan provide for customary
events of default including, among other things, payment defaults, breach of representations and warranties, and insolvency events.
The Company was in compliance with the terms of the PPP loan as of September 30, 2020.
Historically,
we have financed our operations through public and private sales of common stock, issuance of preferred and common stock, convertible
debt instruments, term loans and credit lines from financial institutions, and cash generated from operations. We have taken decisive
action to improve our margins, including fully outsourcing our manufacturing process, streamlining our product portfolio, negotiating
improved vendor contracts and restructuring our selling prices.
10
Critical
Accounting Policies and Estimates
Use
of estimates
The
preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at
the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results
could differ from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory
obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible
assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments
issued for services.
Revenue
Recognition
The
Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers
(“ASC 606”). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services
to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment
when considering the terms of contract(s), which include (1) identifying the contract or agreement with a customer, (2) identifying
our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction
price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied.
The
Company does not have any significant contracts with customers requiring performance beyond delivery, and contracts with customers
contain no incentives or discounts that could cause revenue to be allocated or adjusted over time. Shipping and handling activities
are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised
service to the customer. Revenue and costs of sales are recognized when control of the products transfers to our customer, which
generally occurs upon shipment from our facilities. The Company’s performance obligations are satisfied at that time.
All
of the Company’s products are offered for sale as finished goods only, and there are no performance obligations required
post-shipment for customers to derive the expected value from them.
The
Company does not allow for returns, except for damaged products when the damage occurred pre-fulfillment. Damaged product returns
have historically been insignificant. Because of this, the stand-alone nature of our products, and our assessment of performance
obligations and transaction pricing for our sales contracts, we do not currently maintain a contract asset or liability balance
for obligations. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.
Recent
Accounting Pronouncements
See
Note 2 of the Notes to Condensed Financial Statements for a discussion of recent accounting pronouncements.
Item
3. Quantitative and Qualitative Disclosures About Market Risk.
A
smaller reporting company is not required to provide the information required by this Item.
Item
4. Controls and Procedures.
Evaluation
of Disclosure Controls and Procedures
Under
the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer,
we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Securities and Exchange Act
of 1934 Rules 13a-15(f). Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that
the Company’s disclosure controls and procedures were not effective as of September 30, 2020. As of September 30, 2020,
management’s assessment identified the following material weaknesses in the Company’s internal control over financial
reporting:
11
Outsourced
IT Service Providers - The Company relies upon a variety of outsourced Information Technology (IT) service providers for key
elements of the technology infrastructure impacting its financial reporting process. Certain of these outsourced IT service providers
could not provide System and Organization Controls (SOC) reports. The Company did not have controls designed to assess the design
and operation of internal controls pertaining to these outsourced IT service providers over the period of reliance. Given that
management did not effectively assess the design and operation of certain outsourced IT service providers’ internal controls,
certain of the Company’s controls over IT systems and business processes were also ineffective, to the extent that they
rely upon information that was subject to the outsourced IT service providers’ control environment.
Segregation
of Duties - The Company did not maintain effective policies to ensure adequate segregation of duties within its accounting
processes. Specifically, due to the size of the Company and the smaller nature of department teams, opportunities are limited
to segregate duties, resulting in inabilities to soundly manage segregation of job responsibilities.
Changes
in Internal Control Over Financial Reporting
There
have been no changes in the Company’s internal control over financial reporting during the three months ended September
30, 2020 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over
financial reporting.
Remediation
Plans
As
disclosed in the section titled “Risk Factors” in Part II, Item 1A of this Quarterly Report, we have begun, with the
oversight of senior management and our audit committee, to implement measures to remediate the identified material weakness. The
execution of our remediation is ongoing and will require validation and testing of the design and operating effectiveness of internal
controls over a sustained period of financial reporting cycles. Management expects to complete its remediation plan by the
end of 2020.
PART
II – OTHER INFORMATION
Item
1. Legal Proceedings
We
are subject to various legal proceedings from time to time in the ordinary course of business, none of which are required to be
disclosed under this Item 1.
Item
1A. Risk Factors
In
addition to the following risk factors and the other information set forth in this Quarterly Report on Form 10-Q, you should carefully
consider the risk factors discussed in Part I, Item 1A of our Annual Report on Form 10-K (our Form 10-K) for the year ended December
31, 2019 and any subsequent filings with the Securities and Exchange Commission (SEC) made prior to the date hereof, which could
materially affect our business, financial condition, results of operations or future results. The risks and uncertainties discussed
below, in our Form 10-K and in any subsequent filings with the SEC made prior to the date hereof are not the only ones facing
our business. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may materially
adversely affect our business, cash flows, financial condition and/or results of operations. The risk factor below updates, and
should be read together with, the risk factors disclosed in Part I, Item 1A of our Form 10-K. Please also read the Cautionary
Notice Regarding Forward-Looking Statements in Part I, Item 2 of this Quarterly Report on Form 10-Q under the heading “Management’s
Discussion and Analysis of Financial Condition and Results of Operations”.
12
COVID-19
and other pandemics, epidemics, or outbreaks of a contagious illness may adversely affect our operating results, cash flows and
financial condition.
COVID-19
coronavirus outbreak and other pandemics, epidemics, or outbreaks of a contagious illness, and similar events, may cause harm
to us, our employees, our customers, our vendors and supply chain partners, and financial institutions, which could have a material
adverse effect on our results of operations, financial condition and cash flows. The impacts may include, but would not be limited
to:
●
Decreased
availability and increased cost of supplies due to increased demand around food and food-related products due to increased
global demand and disruptions along the global supply chains of these manufactures and distributors;
●
Disruption
to operations due to the unavailability of employees due to illness, quarantines, risk of illness, travel restrictions or
factors that limit our existing or potential workforce;
●
Elevated
employee turnover which may increase payroll expense and recruiting-related expenses; and
●
Significant
disruption of global financial markets, which could have a negative impact on us or our customers’ ability to access
capital in the future.
In
addition, we have taken and will continue to take temporary precautionary measures intended to help minimize the risk of COVID-19
to our employees, including requiring administrative and other groups of our employees to work remotely, suspending non-essential
travel and restricting attendance at industry events and in-person work-related meetings. Such measures could have a material
adverse effect on our business.
The
further spread of COVID-19, and the requirements to take action to help limit the spread of the virus, could impact the resources
required to carry out our business as usual and may have a material adverse effect on our results of operations, financial condition
and cash flows. The extent to which COVID-19 will impact our business and our financial results will depend on future developments,
which are highly uncertain and cannot be predicted. Such developments may include the ongoing geographic spread of the virus,
the severity of the disease, the duration of the outbreak and the type and duration of actions that may be taken by various governmental
authorities in response to the outbreak and the impact on the United States and the global economy. Any of these developments,
individually or in aggregate, could materially impact our business and our financial results and condition.
We
have identified material weaknesses in our disclosure controls and procedures and internal control over financial reporting. If
not remediated, our failure to establish and maintain effective disclosure controls and procedures and internal control over financial
reporting could result in material misstatements in our financial statements and a failure to meet our reporting and financial
obligations, each of which could have a material adverse effect on our financial condition and the trading price of our common
stock.
Maintaining
effective internal control over financial reporting and effective disclosure controls and procedures are necessary for us to produce
reliable financial statements. As discussed in Part I, Item 4 – “Controls and Procedures” of this Quarterly
Report on Form 10-Q, we have re-evaluated our internal control over financial reporting and our disclosure controls and procedures
and concluded that they were not effective as of September 30, 2020.
A
material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting such
that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be
prevented or detected on a timely basis. The material weaknesses we identified are (1) ineffective controls over outsourced IT
systems and business processes and (2) inadequate segregation of duties within accounting processes. We identified these material
weaknesses initially as of December 31, 2019. The execution of our remediation commenced in the first fiscal quarter of 2020 and
entails splitting activities where inadequate segregation of duties existed and seeking an outsourced IT provider that can provide
effective controls over outsourced IT systems and business processes. This activity is ongoing and will require validation and
testing of the design and operating effectiveness of internal controls over a sustained period of financial reporting cycles.
Management expects to complete its remediation plan during its fourth fiscal quarter ending December 31, 2020. Implementation
of the Company’s remediation plans is being overseen by senior management and the audit committee.
We cannot assure you that we can effectively
remediate our reported weaknesses or that other significant deficiencies or material weaknesses in our internal control over financial
reporting will not be identified in the future. Any failure to maintain or implement required new or improved controls, or any
difficulties we encounter in their implementation, could result in significant deficiencies or material weaknesses, cause us to
fail to timely meet our periodic reporting obligations, or result in material misstatements in our financial statements. Any such
failure could also adversely affect the results of periodic management evaluations regarding disclosure controls and the effectiveness
of our internal control over financial reporting required under Section 404 and the SEC’s rules. The existence of a material
weakness could result in errors in our financial statements that could result in a restatement of financial statements, cause
us to fail to timely meet our reporting obligations, and cause investors to lose confidence in our reported financial information.
Continued determinations that there are material weaknesses in our internal controls could also reduce our ability to obtain financing
or increase the cost of any financing we obtain and require additional expenditures of both money and our management’s time
to comply with applicable requirements.
We may not be entitled to forgiveness
of our recently received Paycheck Protection Program Loan, and our application for the Paycheck Protection Program Loan could
in the future be determined to have been impermissible.
On April 20, 2020, we were granted a Paycheck
Protection Program loan (the “PPP loan”) under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES
Act”) administered by the U.S. Small Business Administration (the “SBA”) in the aggregate amount of $770,000
pursuant to the Paycheck Protection Program (the “PPP”) under the CARES Act. The PPP loan agreement is dated April
20, 2020, matures on April 20, 2022, bears interest at a rate of 1% per annum, with the first six months of interest deferred,
is payable monthly commencing on November 2020, and is unsecured and guaranteed by the U.S. Small Business Administration. The
loan term may be extended to April 20, 2025, if mutually agreed to by the Company and lender. The PPP loan may be prepaid at any
time prior to maturity with no prepayment penalties. Under the CARES Act, as amended in June 2020, loan forgiveness is generally
available for the sum of documented payroll costs, covered rent payments, covered mortgage interest and covered utilities during
the “Covered Period”, which is 8 weeks or 24 weeks (at the election of the Company) beginning on the date of the first
disbursement of the PPP Loan. We will be required to repay any portion of the outstanding principal that is not forgiven, along
with accrued interest, and we cannot provide any assurance that we will be eligible for loan forgiveness, that we will apply for
forgiveness, or that any amount of the PPP Loan will ultimately be forgiven by the SBA. In order to apply for the PPP Loan, we
were required to certify, among other things, that the current economic uncertainty made the PPP Loan request necessary to support
our ongoing operations. We made this certification in good faith after analyzing, among other things, the maintenance of our workforce,
our need for additional funding to continue operations, and our ability to access alternative forms of capital in the current
market environment to offset the effects of the COVID-19 pandemic. Following this analysis, we believe that we satisfied all eligibility
criteria for the PPP Loan, and that our receipt of the PPP Loan is consistent with the broad objectives of the CARES Act. The
certification described above is subject to interpretation. On April 23, 2020, the SBA issued guidance stating that it is unlikely
that a public company with substantial market value and access to capital markets will be able to make the required certification
in good faith. The lack of clarity regarding loan eligibility under the Paycheck Protection Program has resulted in significant
media coverage and controversy with respect to public companies applying for and receiving loans. If, despite our good-faith belief
that given our circumstances we satisfied all eligible requirements for the PPP Loan, we are later determined to have not been
in compliance with these requirements or it is otherwise determined that we were ineligible to receive the PPP Loan, we may be
required to repay the PPP Loan in its entirety and/or be subject to additional penalties. Should we be audited or reviewed by
federal or state regulatory authorities as a result of filing an application for forgiveness of the PPP Loan or otherwise, such
audit or review could result in the diversion of management’s time and attention and the incurrence of additional costs.
Any of these events could have a material adverse effect on our business, results of operations and financial condition.
13
Item
2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item
3. Defaults Upon Senior Securities
None.
Item
4. Mine Safety Disclosures
Not
applicable.
Item
5. Other Information
None.
Item
6. Exhibits
Exhibit
No.
Description
31.1
Certification
of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
31.2
Certification
of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
32.1
Certification
of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
32.2
Certification
of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
101.INS
XBRL
Instance Document*
101.SCH
XBRL
Taxonomy Extension Schema Document*
101.CAL
XBRL
Taxonomy Extension Calculation Linkbase Document*
101.DEF
XBRL
Taxonomy Extension Definition Linkbase Document*
101.LAB
XBRL
Taxonomy Extension Label Linkbase Document*
101.PRE
XBRL
Taxonomy Extension Presentation Linkbase Document*
*filed
herewith
In
accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed.
Furnished
herewith, XBRL (Extensive Business Reporting Language) information is furnished and not filed or a part of a registration statement
or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.
14
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Reed’s,
Inc.
(Registrant)
Date:
November 9, 2020
/s/
Norman E. Snyder, Jr.
Norman
E. Snyder, Jr.
Chief
Executive Officer
(Principal
Executive Officer)
Date:
November 9, 2020
/s/
Thomas J. Spisak
Thomas
J. Spisak
Chief
Financial Officer
(Principal
Financial Officer)
15
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.